Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated diseases.
Takeda Canada Inc. (Takeda) has entered into a contract with Canadian Blood Services (CBS) for GLASSIA ® (alpha-1 proteinase inhibitor) resulting from CBS’s request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.
858 Therapeutics Expands Leadership Team to Support Transition to the Clinic Read More »
Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study.
En los confines del universo, existe un proceso cósmico fascinante que da forma a la esencia misma de la materia. La nucleosíntesis primordial, un espectáculo celestial de reacciones nucleares, ha esculpido los elementos básicos desde los primeros momentos del universo. …
Nucleosíntesis primordial, la creación de los primeros elementos Read More »
Metrion Biosciences Limited announced that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Partners and £1 million from existing investor, Gresham House Ventures.
Metrion Biosciences Closes £3.7m New Equity Financing Read More »
La sal, elemento omnipresente en nuestra dieta diaria, desempeña un papel crucial en la salud y el sabor de nuestros alimentos. Sin embargo, el equilibrio entre el disfrute culinario y la salud cardiovascular es delicado. Veamos cuánta sal podemos consumir de manera sana, desmitificand …
PureTech Health plc reports on the key progress made across its Wholly Owned Programs2 and Founded Entities3 in 2023, announces two new Founded Entities and provides an update on cash and operational runway guidance.
bluebird bio, Inc. announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, before deducting underwriting discounts and commissions.
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock Read More »
Biocytogen Pharmaceuticals Co., Ltd. announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc.
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences Read More »
